CytomX Therapeutics Inc. has announced several upcoming milestones in its clinical development programs for 2026. The company plans to present Phase 1 colorectal cancer expansion data for CX-2051 (varsetatug masetecan) in the first quarter of 2026. Additionally, a Phase 1 combination study of varsetatug masetecan with bevacizumab in colorectal cancer is set to begin in the first quarter of 2026, with initial data expected in the first half of 2027. For CX-801, a masked interferon-alpha-2b, initial Phase 1 combination data with KEYTRUDA® (pembrolizumab) in melanoma is anticipated by the end of 2026. Earlier, CX-801 monotherapy biomarker data in advanced melanoma patients were presented at the 2025 Society of Immunotherapy of Cancer Annual Meeting. Further updates and presentations are scheduled, including the 44th Annual JP Morgan Healthcare Conference on January 14, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytomX Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9622008) on January 08, 2026, and is solely responsible for the information contained therein.